A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " AnaPath Research

AnaPath Research

Table of Contents
Table of Contents

AnaPath Researchは、バルセロナ近郊に拠点を置き、製薬やバイオテクノロジー、農業、化学などさまざまな業界向けの研究開発サービスを提供する、グローバルなCROです。こちらの記事では、同社の特徴や保有する病態モデルに関する情報などを調査し、まとめました。

AnaPath Researchが請け負う非臨床試験

幅広い安全性評価を実施

AnaPath Researchでは、新薬候補物質の安全性の確認を行うため、多岐にわたるin vivo(生体内)試験に対応しています。一般的な反復投与毒性試験や生殖・発生毒性試験、中枢系から心血管系を評価する安全性薬理試験まで対応が可能となっています。豊富な経験を持った専門チームにより、初期段階から包括的なリスク評価を実施することによって、医薬品の開発をサポートしています。

バイオ医薬品にも対応する分析

低分子化合物のほか、組換えタンパク質やモノクローナル抗体、遺伝子治療薬などの生物学的製剤(バイオ医薬品)に対する分析サービスの提供を行っています。薬物動態(PK)や、トキシコキネティクス(TK)のメソッド開発・検証に加えて、抗薬物抗体(ADA)の測定、バイオマーカーの定量といったように、規制要件を満たすための専門的な生体分析について幅広くカバーしています。

GLP準拠・AAALAC認証に基づいた品質基準

同社は、医薬品安全試験の実施基準であるGLP(優良試験所基準)の認証施設であり、信頼性のある試験データの提供を行っています。さらに、国際的な動物福祉機関であるAAALACからの認定も受けており、倫理的かつ適切な対応を徹底しています。また、長年の経験を持った品質保証チームによって厳格な監査体制が敷かれています。

AnaPath Researchが保有する病態モデル一例

多様な動物モデルを選定・運用している

AnaPath Researchは自社施設で直接試験を受託するCROです。安全性評価や毒性試験を実施するため、げっ歯類(ラットやマウス)から非げっ歯類(イヌやミニブタ、非ヒト霊長類)まで、それぞれの化合物が持つ特性に応じた多様な動物モデルを適切に選定・運用しています。

AnaPath Researchの非臨床試験事例

さまざまな化合物の安全評価試験の実績を持つ

AnaPath Researchの公式ホームページでは、具体的な非臨床試験の事例は掲載されていませんでしたが、同社では多岐にわたる化合物の安全性評価試験を実施しています。

安全性評価試験に関する個別のスポンサー名や具体的な開発化合物の機密保持のため、詳細な試験事例は非公開となっていますが、同社では前身となる試験施設の時代から数十年にわたって、医薬品や医療機器、農薬といったように幅広い分野においてGLP準拠試験を実施し、各国の承認申請に貢献してきた実績を持っています。

AnaPath Researchの企業情報

Address Barcelona, Spain
Tel +34 93 719 03 61
Website https://www.anapathresearch.com/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services